The proportion of IPD due to serotypes included in PCVs in use was low in mature PCV10 and PCV13 settings. Serotype distribution differed between PCV10 and PCV13 sites and age groups. Higher-valency PCVs target most remaining IPD and are expected to ex...
Long-term use of PCV10 or PCV13 reduced IPD substantially in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately two-fold to three-fold by 6 years after introduction of PCV10 or PCV13. Continuing serotyp...
Pneumococcal conjugate vaccine (PCV) introduction has substantially reduced the global burden of pneumococcal disease and mortality. A 2019 modelling study assuming implementation in every country estimated that 13-valent PCV (PCV13) vaccination could ...
Treatment with ceftolozane–tazobactam resulted in higher rates of clinical success compared with ceftazidime–avibactam for invasive infections due to multidrug-resistant P aeruginosa. Differences were driven by improved response rates for patients with...
Pseudomonas aeruginosa is responsible for 14·3% of hospital-acquired bloodstream infections in patients in intensive care units (ICUs).1 In Europe, resistance to piperacillin–tazobactam, ceftazidime, carbapenems, fluoroquinolones, and aminoglycosides w...
The west Africa Ebola disease epidemic (2014–16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure in many ways—a slow, cumbersome, and disjointed effort by a global ar...
The west Africa Ebola disease epidemic (2014–16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure in many ways—a slow, cumbersome, and disjointed effort by a global ar...
A key lesson from the west Africa (2014–16) Ebola disease epidemic was that outbreak responses fail when they respond to patients through a narrow clinical lens without considering the broader community and social context of care. Here, in the second o...
A key lesson from the west Africa (2014–16) Ebola disease epidemic was that outbreak responses fail when they respond to patients through a narrow clinical lens without considering the broader community and social context of care. Here, in the second o...
In April, 2024, we reported on mid-season findings from NIRSE-GAL, a population-based longitudinal study on the effectiveness of universal nirsevimab prophylaxis against respiratory syncytial virus (RSV) in infants aged 0–24 months in Galicia, Spain.1 ...
As of November, 2024, SARS-CoV-2 omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2),1 KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC2—a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3)—have been circulating in seve...
The deployment of the RTS,S/AS01 vaccine and the prequalification of R21/Matrix-M vaccine are important milestones that target child health and survival, especially in Africa.1 Sub-Saharan Africa bears approximately 94% of global malaria cases and deat...
RH5.1/Matrix-M appears safe and highly immunogenic in African children and shows promising efficacy against clinical malaria when given in a delayed third-dose regimen. This trial is ongoing to further monitor efficacy over time.
We read with interest the Correspondence by Concetta Castilletti and colleagues1 on Oropouche virus cases imported into Europe and we agree with the need for accurate identification and timely diagnosis of Oropouche virus cases. Oropouche virus has eme...
The publication of a phase 3 trial by Terry Nolan and colleagues in The Lancet Infectious Diseases marks a key step towards licensing a new GSK vaccine (MenABCWY) which targets five Neisseria meningitidis serogroups.1 The vaccine combines a conjugate v...
This study demonstrates breadth of immune response against a panel of 110 MenB strains for the MenB component of the investigational MenABCWY vaccine, when administered as a 0–6 months schedule to the target population of adolescents and young adults, ...